Injectable chlorpheniramine/hyoscyamine recalled for sterility assurance failure
Pharmacy Innovations has recalled Chlorpheniramine/Hyoscyamine injectable medication nationwide due to insanitary facility conditions identified during FDA inspection that compromise product sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves a high-risk product category (sterile injectables) with documented sterility assurance failure from facility conditions. No reported illnesses or injuries appear in the source material, placing this at Score 3 (High) per the rubric criterion for risk-of-harm products without documented injury.
Plain-English summary
Pharmacy Innovations, located at 2936 W 17th St., Erie, Pennsylvania, has recalled Chlorpheniramine/Hyoscyamine 10 mg/0.25 mg per 1 mL injectable medication nationwide. An FDA inspection revealed insanitary conditions at the manufacturing facility that compromise the sterility assurance for this injectable product.
Chloropheniramine/Hyoscyamine is an Rx-only antihistamine and anticholinergic medication administered by injection. The recalled product code is t20221026@41 and was distributed nationwide. Injectable medications require strict sterility to ensure safety.
Healthcare providers who have this product should verify their inventory and quarantine any affected units. Patients who have received this medication should contact their healthcare provider regarding potential exposure from this recall.
The recalled product
- Product
- Chlorpheniramine/Hyoscyamine (1ML) 10MG/0.25MG/ML Injectable, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Manufacturer
- Pharmacy Innovations
- Hazard
- lack-of-sterility
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221026@41
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27